Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study

Zhang, Yang; Wu, Shanshan; Xia, Yuqing; Wang, Ni; Zhou, Lin; Wang, Jing; Fang, Renfei; Sun, Feng; Chen, Ming-Ting; Zhan, Siyan

doi:10.12659/msm.904682

Cited by 52 publications

(82 citation statements)

References 18 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other similar studies conducted elsewhere, however, did not report gout as an adverse effect [6–15]. Gout is a painful rheumatic disease characterized by deposition of uric acid crystals in the joints and elevation of serum uric acid levels, leading to acute inflammatory arthritis [16, 17].…”

Section: Introductionmentioning

confidence: 99%

Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study

Russom

Tesfaselassie

Goitom

et al. 2019

Tuberculosis Research and Treatment

View full text Add to dashboard Cite

Though the incidence of gout in general population is less than 5% (globally), a study conducted in Eritrea among patients with multidrug resistant tuberculosis (MDR-TB) revealed a higher incidence (25%). Other similar studies conducted elsewhere, however, did not report gout as an adverse effect. It is unknown why a higher incidence of gout is being reported in Eritrea compared to similar studies from other countries. The objective of this study is therefore to explore risk factors for the increased risk of incident gout among MDR-TB patients in Eritrea. A case-control study was conducted in Merhano MDR-TB National Referral Hospital in Eritrea. All MDR-TB patients diagnosed with gout between June 2011 and June 2018 were considered as cases. Controls matched by age, sex, and cumulative drug exposure time were selected from the same study population (1:1 ratio). A total of 84 MDR-TB patients, 42 cases and 42 controls, were included in this study. No patient from the control group has comorbidities, while six patients from the case group have diabetes (χ2 = 6.46, df=1, p=0.026). Patients having tachycardia (OR=3.26, 95% CI=1.28, 8.27), alopecia (OR=3.11, 95% CI=1.00, 9.67), and gastrointestinal upset (OR=3.17, 95% CI=1.26, 7.96) as adverse effects and being on prolonged use of propranolol (OR=3.26, 95% CI=1.28, 8.27) were found to be more likely to develop incident gout compared to their controls. In conclusion, MDR-TB patients with diabetes mellitus, tachycardia, alopecia, and gastrointestinal upset and on prolonged use of propranolol tablet had increased risk of incident gout.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study

Russom

Tesfaselassie

Goitom

et al. 2019

Tuberculosis Research and Treatment

View full text Add to dashboard Cite

show abstract

“…The adverse events reports on MDR-TB treatment has increased and known to be related to poor treatment outcome [3]. Zhang Y et al (2017) reported that the number of successful treatment of MDR-TB reach only 52%. The high level of poor outcome consisted of died patients (9.4%), discontinued treatment (13.7%) and not evaluated (5.1%) [4].…”

Section: Introductionmentioning

confidence: 99%

“…Zhang Y et al (2017) reported that the number of successful treatment of MDR-TB reach only 52%. The high level of poor outcome consisted of died patients (9.4%), discontinued treatment (13.7%) and not evaluated (5.1%) [4]. World Health Organization (WHO) also reports the same situation: successful treatment MDR-TB is only 54% while global treatment success rate is 83%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence social and healthcare support on psychiatric adverse events in MDR-TB patient

Reviono

Harsini

Aphridasari

et al. 2018

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Multidrug resistance tuberculosis (MDR-TB) is a continuing threat because the treatment is rather toxic. One of the causes of poor treatment outcome is due to the adverse events, especially the occurrence of psychiatric adverse events. Methodology: The two cases presented in this paper are MDR-TB patients with psychiatric adverse events related to depression spectrum. The diagnosis of psychiatric adverse events was done by psychiatrist in the referral hospital. Results: The treatment of MDR-TB and psychiatric adverse event was carried out simultaneously. One of the patients was able to manage the adverse events, but the other was not. The management of psychiatric adverse events need to be performed carefully. Social support of family and friends was received by the successful patient, while the other was not fully supported, thus failed the treatment. Conclusion: The social support provided by the family and friends are precious for the successful treatment of MDR-TB psychiatric adverse events. The availability of healthcare personnel who is able to recognize the symptoms early is needed in the community healthcare service in order to properly detect and manage the psychiatric adverse events on MDR-TB patients.

show abstract

“…The use of adjunct therapies such as surgery (6), hospitalization, and patient support for treatment adherence (7), such as patient-centered directly observed therapy (DOT), also varies by program. The occurrence of adverse drug reactions to second-line TB drugs is common (1,8) and may be managed differently in different settings, particularly the permanent withdrawal of certain agents. All those factors result in wide variation in patient management and outcomes.…”

mentioning

confidence: 99%